Clinical Trial

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

Completed
View on ClinicalTrials.gov →
Summary
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
Protocol Amendment History 3 changes
critical Trial completed 2026-05-28
notable Primary completion moved earlier: 2027-02-09 -> 2026-05-06 2026-05-28
minor Completion moved earlier: 2027-02-09 -> 2026-05-06 2026-05-28
Trial Details
NCT Number NCT07450820
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease
Enrollment 12,894 participants
Start Date 2026-02-18
Primary Completion 2026-05-06 (estimated)
Study Completion 2026-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-27